😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines

Published 05/26/2023, 04:57 PM
Updated 05/26/2023, 05:01 PM
© Reuters. FILE PHOTO: Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron
PFE
-
MRNA
-

By Blake Brittain

(Reuters) - Biotech company Alnylam Pharmaceuticals Inc filed new lawsuits on Friday against Pfizer Inc (NYSE:PFE) and Moderna (NASDAQ:MRNA) Inc in Delaware federal court, again claiming that the companies' COVID-19 vaccines infringe its patents.

The new lawsuits mark the third time Alnylam has sued Pfizer and Moderna in Delaware for allegedly violating its patent rights in lipid nanoparticle (LNP) technology, which the vaccines use to deliver genetic material into the body.

Alnylam is again seeking an unspecified share of royalties from the companies' vaccine sales. Pfizer earned $37.8 billion from sales of its COVID-19 vaccine Comirnaty last year, while Moderna made $18.4 billion from its vaccine Spikevax.

Representatives for Alnylam, Moderna and Pfizer did not immediately respond to requests for comment on the new lawsuits. Moderna and Pfizer have denied the allegations in the earlier cases and argued that Alnylam's patents are invalid.

Cambridge, Massachusetts-based Alnylam first sued Moderna and Pfizer last March. It filed another pair of complaints last July over an additional LNP patent, which were later consolidated with its earlier lawsuits.

The lawsuits filed Friday include four new infringement claims against Pfizer and three against Moderna.

The complaints are part of a wave of patent lawsuits filed by biotech companies over COVID-19 vaccines, including a case brought by Moderna against Pfizer last year in Massachusetts.

Alnylam told the Delaware court that it pioneered LNP technology "essential" to the mRNA-based vaccines more than a decade ago. It also said it gave Moderna confidential information about the technology in 2014 during discussions about a potential collaboration.

The cases are Alnylam Pharmaceuticals Inc v. Moderna Inc, U.S. District Court for the District of Delaware, No. 1:23-cv-00580 and Alnylam Pharmaceuticals Inc v. Pfizer Inc, U.S. District Court for the District of Delaware, No. 1:23-cv-00578.

For Alnylam: William Gaede, Sarah Columbia, Sarah Fischer, Ian Brooks and Bhanu Sadasivan of McDermott Will & Emery

For Moderna and Pfizer: attorney information not available

Read more:

Alnylam files patent infringement lawsuits against Pfizer, Moderna

© Reuters. FILE PHOTO: Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron

Pfizer, Moderna COVID-19 vaccines infringe new Alnylam patent, lawsuits say

Pfizer says COVID-19 vaccine lawsuit is based on bogus patent

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.